Emily R Whelan
Overview
Explore the profile of Emily R Whelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beetler D, Giresi P, Di Florio D, Fliess J, McCabe E, Watkins M, et al.
Front Immunol
. 2025 Jan;
15():1468969.
PMID: 39835120
Introduction: Extracellular vesicles (EVs) can potently inhibit inflammation yet there is a lack of understanding about the impact of donor characteristics on the efficacy of EVs. The goal of this...
2.
Di Florio D, Weigel G, Gorelov D, McCabe E, Beetler D, Shapiro K, et al.
Biol Sex Differ
. 2024 Dec;
15(1):104.
PMID: 39696682
Background: Myocarditis is an inflammation of the heart muscle most often caused by viral infections. Sex differences in the immune response during myocarditis have been well described but upstream mechanisms...
3.
Darakjian A, Bhutani M, Fairweather D, Kocsis S, Fliess J, Khatib S, et al.
Rheumatol Adv Pract
. 2024 Dec;
8(4):rkae134.
PMID: 39660107
Objectives: Patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) experience a wide array of symptoms and system disorders. This study aimed to identify whether differences occurred in...
4.
Knight D, Bruno K, Singh A, Munipalli B, Gajarawala S, Solomon M, et al.
Front Cardiovasc Med
. 2024 Apr;
11:1332508.
PMID: 38562189
Background: Defective connective tissue structure may cause individuals with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD) to develop cardiac defects. Methods: We conducted a retrospective chart review of...
5.
Di Florio D, Macomb L, Giresi P, Beetler D, Bonvie-Hill N, Shapiro K, et al.
iScience
. 2023 Dec;
26(12):108493.
PMID: 38146431
Myocarditis is typically caused by viral infections, but most cases are thought to be subclinical. Echocardiography is often used for initial assessment of myocarditis patients but is poor at detecting...
6.
Senefeld J, Gorman E, Johnson P, Moir M, Klassen S, Carter R, et al.
Mayo Clin Proc Innov Qual Outcomes
. 2023 Oct;
7(5):499-513.
PMID: 37859995
Objective: To examine the association of COVID-19 convalescent plasma transfusion with mortality and the differences between subgroups in hospitalized patients with COVID-19. Patients And Methods: On October 26, 2022, a...
7.
Beetler D, Bruno K, Watkins M, Xu V, Chekuri I, Giresi P, et al.
Small
. 2023 Aug;
19(49):e2303317.
PMID: 37612820
Patients with viral myocarditis are at risk of sudden death and may progress to dilated cardiomyopathy (DCM). Currently, no disease-specific therapies exist to treat viral myocarditis. Here it is examined...
8.
Laryngological Complaint Prevalence in Hypermobile Ehlers-Danlos or Hypermobility Spectrum Disorders
Menton S, Fairweather D, Bruno K, Thompson C, Candelo E, Darakjian A, et al.
Laryngoscope
. 2023 Aug;
134(2):773-778.
PMID: 37597175
Objective: The aim was to study laryngological complaints in patients with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD). Methods: A total of 363 patients met inclusion for the...
9.
Knight D, Confiado S, Bruno K, Fairweather D, Seymour-Sonnier A, Jain A, et al.
SN Compr Clin Med
. 2022 Jul;
4(1):138.
PMID: 35811641
In a large academic medical center, patient requests from the community and internal referrals for evaluation of suspected hypermobility conditions were being denied consultation because services specific to this condition...
10.
Krishnarao K, Bruno K, Di Florio D, Edenfield B, Whelan E, Macomb L, et al.
J Clin Med
. 2022 Jun;
11(12).
PMID: 35743613
As survival in breast cancer patients from newer therapies increases, concerns for chemotherapy-induced cardiotoxicity (CIC) have offset some of these benefits, manifesting as a decline in left ventricular ejection fraction...